6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April, 2013.

Commission File Number ________________

Novogen Limited

(Translation of registrant’s name into English)

1-7 Waterloo Road, Macquarie Park, NSW, Australia

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 Form 20-Fx Form 40-Fo

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): o

Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  o

Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.  Yes  o No x

If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Novogen Limited (Registrant)

(Signature) *

Andrew Bursill

Date 8 April 2013

* Print the name and title under the signature of the signing officer.

EX-99

ASX Release

8 April 2013

Novogen Announces Successful Isolation of Most Potent Form of CS-6

CS-6 is the lead anti-cancer drug candidate being developed by Novogen as a

first-in-class comprehensive cancer therapy.

In manufacturing terms, CS-6 is classified as a chiral molecule, meaning that the

molecule can exist in both left- and right-hand forms known as enantiomers. This

tendency is common to most drugs as well as to many naturally-occurring

molecules.

This significance of this to the pharmaceutical industry is that enantiomers often

differ in their biological activity, with one form being more active than the other

form. This difference can lead to the weakest form inhibiting the most active

form. Where that happens, the enantiomers need to be separated and used in

isolation.

The initial biological studies on CS-6 have been conducted using a mixture of the

two enantiomers. This is a typical research strategy in early-stage drug

development to save time and costs. Purification and manufacture of the pure

left- and right hand forms is only undertaken once a molecule has demonstrated

significant promise in pre-clinical studies. With CS-6 now having shown that

promise, the Company recently undertook manufacture of pure left- and right-

hand forms, representing a significant advance in its developmental pathway.

The two CS-6 enantiomers were screened recently in vitro for activity against

brain cancer (glioblastoma and meduloblastoma) cell lines. Analysis of this data

today shows that one CS-6 enantiomer is approximately 200 times more active

than the alternate form of CS-6 against all brain cancer cell lines tested.

Novogen Chief Scientific Officer, Dr Andrew Heaton, today said, “The ability to

manufacture CS-6 in both left- and right-hand forms represents a significant

milestone in the development of this compound. The indication that one form of

CS-6 is active at nanomolar concentrations against a broad spectrum of brain

cancer lines is exciting and indicates that the earlier potencies we have seen

against cancer cells and cancer stem cells are likely to be even greater with the

purified enantiomer. We are now positioned to rapidly progress CS-6 to the

clinic.”

About Novogen

Novogen Ltd is a public Australian biotechnology company whose shares trade

on both the Australian Stock Exchange (symbol ‘NRT’) and NASDAQ (symbol

‘NVGN’).  The Company is based in Sydney, Australia and is focused on the

development of a family of novel anti-cancer drugs based on comprehensive

anti-cancer activity against both cancer cells and cancer stem cells. The

Company’s inaugural drug candidate is CS-6.

About CS-6

CS-6 belongs to a new class of drug candidates intended to treat most forms of

cancer in a comprehensive manner, targeting both cancer cells and their

progenitor cells …. cancer stem cells. CS-6 shows broad anti-proliferative and

cytotoxic activity against human cancer cells and ovarian cancer stem cells. CS-6

also has been designed deliberately to meet the major known criteria for

crossing the blood-brain barrier, and for that reason is being developed as a

first-line for the treatment of glioblastoma multiforme, the main form of primary

brain cancer.

About Cancer Stem Cells

Cancer stem cells (CSC) (or tumour-initiating cells) are believed to be a

subpopulation of cells within many types of cancer that are responsible for

driving the growth and spread of the cancer. CSC typically are resistant to

radiotherapy and chemotherapy and are thought to be responsible for cancer

recurrence following therapy. Targeting CSC is a new direction in oncology drug

development as a means of preventing cancer recurrence.

Further information

Contact Dr Graham Kelly, Chief Executive Officer.

T:  (61 2) 9878 0088

M: (61) 0459 200 095

E: Graham.Kelly@novogen.com

Further information is available on the Company’s web site, www.novogen.com